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ABSTRACT -Lactam antibiotics are the drugs of choice to treat pneumococcal infections. The spread of -lactam-resistant
pneumococci is a major concern in choosing an effective therapy for patients. Systematically tracking -lactam resistance could
benefit disease surveillance. Here we developed a classification system in which a pneumococcal isolate is assigned to a “PBP
type” based on sequence signatures in the transpeptidase domains (TPDs) of the three critical penicillin-binding proteins
(PBPs), PBP1a, PBP2b, and PBP2x.We identified 307 unique PBP types from 2,528 invasive pneumococcal isolates, which had
knownMICs to six-lactams based on broth microdilution. We found that increased -lactamMICs strongly correlated with
PBP types containing divergent TPD sequences. The PBP type explained 94 to 99% of variation inMICs both before and after
accounting for genomic backgrounds defined bymultilocus sequence typing, indicating that genomic backgrounds made little
independent contribution to -lactamMICs at the population level. We further developed and evaluated predictive models of
MICs based on PBP type. Compared to microdilutionMICs, MICs predicted by PBP type showed essential agreement (MICs
agree within 1 dilution) of>98%, category agreement (interpretive results agree) of>94%, a major discrepancy (sensitive iso-
late predicted as resistant) rate of<3%, and a very major discrepancy (resistant isolate predicted as sensitive) rate of<2% for all
six-lactams. Thus, the PBP transpeptidase signatures are robust indicators of MICs to different -lactam antibiotics in clinical
pneumococcal isolates and serve as an accurate alternative to phenotypic susceptibility testing.
IMPORTANCE The human pathogen Streptococcus pneumoniae is a leading cause of morbidity and mortality worldwide.
-Lactam antibiotics such as penicillin and ceftriaxone are the drugs of choice to treat pneumococcal infections. Some pneumo-
coccal strains have developed -lactam resistance through altering their penicillin-binding proteins (PBPs) and have become a
major concern in choosing effective patient therapy. To systematically track and predict -lactam resistance, we obtained the
sequence signatures of PBPs from a large collection of clinical pneumococcal isolates using whole-genome sequencing data and
found that these “PBP types” were predictive of resistance levels. Our findings can benefit the current era of strain surveillance
when whole-genome sequencing data often lacks detailed resistance information. Using PBP positions that we found are always
substituted within highly resistant strains may lead to further refinements. Sequence-based predictions are accurate andmay
lead to the ability to extract critical resistance information from nonculturable clinical specimens.
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Streptococcus pneumoniae (pneumococcus) is an important hu-man pathogen causing large numbers of cases of pneumonia,
bacteremia, and meningitis globally. Penicillin and other
-lactam antibiotics have been the primary means of treating
pneumococcal infections for decades. The first detection of a
pneumococcus with reduced penicillin susceptibility (MIC 
0.12g/ml) occurred in 1967 inAustralia (1); in theUnited States,
penicillin-nonsusceptible pneumococci became an emerging
problem during the 1990s (2–7). Introduction of pneumococcal
conjugated vaccines (PCVs), which target 7 to 13 of themore than
90 knownpneumococcal serotypes, was associatedwith a decrease
in resistant pneumococcal infections (8–10). Nonetheless, emer-
gence and spread of -lactam resistance, particularly among sero-
types not targeted by PCVs, remains a major concern. Systemati-
cally tracking -lactam resistance is critical for both disease
surveillance and choosing effective therapy for patients. A penicil-
lin MIC of 0.12 g/ml is considered resistant for pneumococcal
meningitis, while for nonmeningitis disease, a 16-fold increased
MIC for this antibiotic is considered susceptible. There is an ex-
traordinary range of -lactam resistance expressed by different
clinically relevant pneumococcal strains. For these reasons, it is
critical to have the capability to accurately predict a wide range of
MICs for -lactam antibiotics.
In clinical isolates, -lactam resistance is primarily driven by
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alterations in the transpeptidase domains (TPDs) of penicillin-
binding proteins (PBPs) that reduce affinity for the antibiotics to
attach to these sites. Growth inhibition of wild-type pneumococ-
cal strains by most -lactam antibiotics is primarily due to inhi-
bition of PBP2x (11). The primary role of PBP1a, PBP2b, and
PBP2x for determining-lactamMICswas indicatedwhen amix-
ture of three alleles from a single highly penicillin-resistant pneu-
mococcal strain was used to transform a susceptible strain to
achieve the same level of resistance (12). Published evidence sup-
ports that changes within PBP2b and PBP2x are essential for
lower-level-lactam resistance (13–15), with these and additional
changes within PBP1a essential for high-level resistance (16, 17).
Other changes both within and outside the PBPs presumably
compensate for fitness costs (18–20). Many resistant pbp alleles
enter into the pneumococcal population through interspecies re-
combination with othermitis groupmembers of the Streptococcus
genus (21–23). Subsequent intraspecies recombination and mu-
tation further diversify pbp loci, resulting in a large number of pbp
alleles associated with a broad range of -lactam MICs.
To effectively track genotypes and their associated MICs of
-lactam-nonsusceptible pneumococci, we propose a classifica-
tion system in which a pneumococcal isolate is assigned a “PBP
type” based on amino acid residues in the TPDs of the threemajor
PBPs, PBP1a, PBP2b, and PBP2x. Here we report 307 PBP types
identified from 2,528 invasive S. pneumoniae isolates and use the
PBP type to predict-lactamMICs asmeasured bymicrodilution.
Our results indicate that the PBP typing system will provide an
alternative to conventional susceptibility testing and might im-
prove our ability to extract critical resistance information from
nonculturable clinical specimens.
RESULTS
Increased -lactam MIC associated with PBP types containing
divergent TPD variants. From the 2,528 S. pneumoniae isolates
studied here, we identified 68, 78, and 118 uniqueTPDamino acid
sequences for PBP1a, PBP2b, and PBP2x, respectively. We ob-
served 307 unique combinations of these sequences which defined
the PBP types. The 2,528 isolates exhibited a wide range of
-lactamMICs (Table 1) asmeasured bymicrodilution. Figure 1A
compares the median penicillin (PEN) MICs across all 307 PBP
types. Typical PBP types associated with PEN-susceptible isolates
were 2-0-2 (n 248), 1-2-2 (n 162), and 0-0-2 (n 134) (PBP
type naming system explained in “Isolates and Characterization”
in Materials and Methods). PBP types with intermediate PEN re-
sistance (median MIC, 0.12 to 1 g/ml) included 0-1-1 (n 61),
8-0-11 (n 44), and 0-29-11 (n 56). Common PBP types with
the median PEN MIC of 2 g/ml were 13-11-16 (n  121),
15-12-18 (n 53), and 27-36-8 (n 42). PEN-resistant PBP types
tended to show 30 or more amino acid changes in the three TPDs
compared to the susceptible PBP type 2-0-2 (Fig. 1A). In fact,
there was a strong positive correlation between the number of
amino acid changes and PEN MIC (  0.82 [see Fig. S1 in the
supplemental material]).
We classified aTPDvariant as “divergent” if it showed less than
90% amino acid sequence identity with the corresponding TPD in
PBP type 2-0-2. Thus, an isolate could harbor 0 to 3 divergent
TPDs in PBP1a, PBP2b, and PBP2x. We observed a stepwise in-
crease in PENMIC as the number of divergent TPDs in an isolate
increased (Fig. 1B).While almost all PEN-susceptible isolates con-
tained no divergent TPDs, isolates containing 1, 2, and 3 divergent
TPDs showed median PEN MICs of 0.25 g/ml, 2 g/ml, and
4 g/ml, respectively. The differences in median PENMICs were
highly significant (P 1 1015 for all pair-wise comparisons by
Mann-Whitney U test). Similar stepwise increases in MICs with
increasing numbers of divergent TPDs were also observed for the
other five -lactams (see Fig. S2 in the supplemental material).
Amino acid changes common to all highly resistant isolates
(PEN MIC of 4 g/ml) appeared to be distributed unevenly
across the TPDs. There were 27 TPD positions in which an amino
acid change relative to PBP type 2-0-2 was found in 100% (n 
253) of highly resistant isolates (Fig. 1A; see Table S1 in the sup-
plemental material). We observed a modestly yet significantly
higher density of such positions within 20 amino acids (AA) from
a TPD active site (Fig. 1C, 0.047 versus 0.021, P 0.038, Fisher’s
exact test).While some of the 27 positions have been implicated in
altering affinity to -lactams, such as T371 and TSQF574– 577 in
TABLE 1 Distribution of -lactam MICs in the study sample according to broth microdilution testing
Antibiotica Parameterb Value for parameterc
PEN MIC (g/ml) 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 NA
No. of isolates 1,702 93 110 121 61 61 140 178 60 1 1
AMO MIC (g/ml) 0.03 0.06 0.12 0.25 0.5 1 2 4 8 8 NA
No. of isolates 1,745 171 84 31 50 67 105 83 155 22 15
MER MIC (g/ml) 0.06 0.12 0.25 0.5 1 1 NA
No. of isolates 1,942 67 46 129 232 28 84
TAX MIC (g/ml) 0.06 0.12 0.25 0.5 1 2 4 8 16 NA
No. of isolates 1,840 120 64 67 180 148 16 26 3 64
CFT MIC (g/ml) 0.5 1 2 4 8 NA
No. of isolates 1618 141 86 17 6 660
CFX MIC (g/ml) 0.5 1 2 2 NA
No. of isolates 2,040 24 40 417 7
a Abbreviations: PEN, penicillin; AMO, amoxicillin; MER, meropenem; TAX, cefotaxime; CFT, ceftriaxone; CFX, cefuroxime.
b The MIC and the number of isolates with the indicated MIC for each antibiotic are shown.
c NA, no MIC data available.
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PBP1a (24), T446 and E476 in PBP2b (25), and T338 in PBP2x
(26), many others were of unclear function.
The PBP type correlated with -lactamMICs across diverse
MLSTs. Our study sample was comprised of isolates with diverse
genomic backgrounds, including 403 different multilocus se-
quence types (MLSTs). The PBP type and MLST were correlated
but not completely overlapping (see Fig. S3 in the supplemental
material), which allowed us to examine the relative contribution
of PBP and genomic background to -lactam MIC. First, we ex-
amined the distribution of PENMICs acrossMLSTs within 9 rep-
resentative PBP types (Fig. 2), of which 3 showed median PEN of
0.03 g/ml (top panel), 3 showed median PEN of 0.12 to
0.25g/ml (middle panel), and another 3 showedmedian PEN of
2 to 4 g/ml (bottom panel). The number of MLSTs observed
within each PBP type ranged from 2 to 18. We found essentially
identical MICs across MLSTs in the susceptible PBP types. For
FIG 1 Amino acid changes in penicillin-binding protein (PBP) transpeptidase domains (TPDs) associated with increased MICs. (A) Each row is a unique PBP
type, and a black bar indicates that the aligned amino acid differed from the amino acid in the reference PBP type 2-0-2. The width of the row is proportional to
the number of isolates. Rows were sorted from top to bottom by decreasing order of median penicillin (PEN) MICs (in micrograms per milliliter) and then by
increasing order of number of isolates. The PBP type 2-0-2 row also shows the start and end amino acid position of each TPD. There were 27 TPD sites in which
an amino acid differed from that in PBP type 2-0-2 in all isolates with PENMICs of4 g/ml (open triangles at the top of the figure); we define these 27 TPD
sites as resistance-associated TPD sites. (B) Boxplot of PENMICs among isolates containing 0, 1, 2, or 3 divergent TPDs. A divergent TPD showed less than 90%
amino acid sequence identity with the corresponding TPD in PBP type 2-0-2. Whiskers indicate the farthest value that is within 1.5 interquartile range (IQR) of
the hinges. (C) Resistance-associated TPD sites weremore frequently found among amino acid sites that are close to an active site (20 amino acids [AAs]). The
three TPD domains contain a total of 914 amino acid sites, which were classified into two groups according to whether the distance to an active site is less than
20 AAs (n 319) or more than 20 AAs (n 595). The frequency of resistance-associated TPD sites in each group is shown. Error bars are 95% CIs.
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example, 244 of the 248 PBP type 2-0-2 isolates were of the same
PENMIC even though they represented 18 different MLSTs. The
resistant PBP types showed slightly more MIC variation (Fig. 2,
middle and bottom panels), but no association between MLST
and PENMIC level (treated as a categorical variable) within a PBP
type was found (P  0.05 by Fisher’s exact test). Similar within-
PBP type MIC distributions were also observed for the other 5
antibiotics (see Fig. S4 in the supplemental material). The results
suggested that PBP type consistently correlated with -lactam
MIC across diverse MLST-defined genomic backgrounds.
The above notion was further supported by an analysis of vari-
ance using mixed-effect models (Table 2). While the MLST-only
model explained 73% to 91% of variations in the log2MIC for the
6 -lactams (Table 2, model 1), the PBP type-only model ex-
plained a higher proportion (94% to 99%) of the variations. In the
model incorporating both the PBP type and the MLST (Table 2,
model 3), the amount of variation attributed to the PBP type re-
mained around 94% to 98%, but the amount of variation attrib-
uted to the MLST dropped to 0.00% to 0.95%. Compared to the
PBP type-only model, adding theMLST improved goodness of fit
minimally and only for 3 of the 6 -lactams (Table 2, model 3
versusmodel 2). The results indicated that after accounting for the
PBP type, genomic background contributed little to -lactam
MICs at the population level.
PBP type as -lactam MIC predictor. The predominant role
of PBP type in explaining MIC variation motivated us to test
whether PBP type, or its corresponding TPD amino acid se-
quences, could be used as a practical predictor of -lactamMICs.
We constructed three predictive models as described in Materials
and Methods. The predicted MICs of the six -lactams generated
by the leave-one-out approach were compared against the mi-
crodilutionMICs (Fig. 3). In isolates of trained PBP types (trained
PBP type explained in “Predictive models of -lactam MIC” in
Materials andMethods),MICs predicted by themodeMIC (MM)
model showed essential agreement (EA) of98%, category agree-
ment (CA) of94%,major discrepancy (maj) rate of3%, lower
FIG 2 Distribution of PENMICs acrossMLSTswithin nine representative PBP types; inmost PBP types, theMICs cluster around1 dilution. Divergent TPDs,
which showed less than 90% amino acid sequence identity with the corresponding TPD in PBP type 2-0-2, are indicated with an asterisk (e.g., 0-1*-1).
TABLE 2 Analysis of variation in log2 (MIC) incorporating random
effects for the PBP type and the MLST for the three models evaluateda
Antibioticb
Variationc explained by:
P valued
Model 1
(MLST
only)
Model 2
(PBP type
only)
Model 3
MLST
PBP
type
Model 3 vs
model 1
Model 3 vs
model 2
PEN 91.3 97.9 0.06 97.8 2 1016 0.10
AMO 91.0 98.7 0.02 98.6 2 1016 0.32
MER 90.4 97.5 0.24 97.3 2 1016 1 108
TAX 89.1 97.9 0.09 97.9 2 1016 0.005
CFT 73.3 94.2 0.00 94.2 2 1016 1
CFX 90.6 98.1 0.95 97.3 2 1016 4 1014
a Models were constructed with the log2-transformed MIC as the dependent variable.
Model 1 included only multilocus sequence type (MLST) as the covariate. Model 2
included only PBP type as the covariate. Model 3 used both PBP type and MLST as
covariates. These models incorporated random effect(s) for all covariate(s). The only
fixed-effect term was the intercept.
b Abbreviations: PEN, penicillin; AMO, amoxicillin; MER, meropenem; TAX,
cefotaxime; CFT, ceftriaxone; CFX, cefuroxime.
c Percentage of variance that is attributed to the indicated model covariate(s).
d The P value of the likelihood ratio test.
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95% confidence interval (95% CI) of the very major discrepancy
(vmj) rate of1.5%, and upper 95% CI of the vmj rate of7.5%
for all six -lactams (Fig. 3). Similar results were observed for the
random forest (RF) and elastic net (EN) models (Fig. 3), except
that the EN model showed a higher vmj rate for PEN than the
other two models did (Fig. 3D). These results supported the pre-
dictedMICby theMMandRFmodels as an acceptable equivalent to
themicrodilutionMIC among the trained PBP types. Predicted PEN
MICsby theMMmodel basedon all isolates are shown inTable S2 in
the supplementalmaterial. FigureS5 showsadiagramindicatinghow
to predict MICs for a specific isolate using these tables.
For isolates of nontrained PBP types (nontrained PBP type
explained in “Predictive models of -lactam MIC” in Materials
and Methods), a generally lower percentage of EA and CA was
observed for predictions made by the three models (Fig. 4A and
B). The RF and EN models appeared to perform slightly better in
EA than the MM model (Fig. 4A). The maj and vmj errors were
also higher among nontrained PBP types (see Fig. S6 in the sup-
plemental material), but the evaluation was limited by the small
sample size, which resulted in wide confidence intervals. For PEN,
a nontrained PBP type differed from its most closely related,
trained PBP type by 1 to 50 AA with a median of 2 AAs (Fig. 4C).
Among the 83 isolates whose nontrained PBP type showed only
1 AAdifference from itsmost closely related, trained PBP type, the
proportion EA for PEN predicted by the MM model (81/83) was
not significantly different fromwhat was observed among isolates
of trained PBP type (2,314/2,355, P 0.66 by Fisher’s exact test).
For every 1 additional AA difference, there was, on average, a 1.09-
fold (95%CI, 1.14 to 1.04) decrease in the odds of being EA [logistic
regression, t(170)  3.69 and P  0.0002]. Thus, the predictive
performance of the MM model decreases significantly for the non-
trained PBP types containingmore than 1 AA difference.
Because the pneumococcal genomic background evolves over
time, we examined whether the MM model prediction perfor-
mance could be affected by the length of time between the training
data set and the testing data set. Isolates in one of the five surveil-
lance years (1998, 1999, 2009, 2012, and 2013) were used as the
training data set for theMMmodel, and the fittedmodel was used
to predict PEN MIC for isolates in subsequent years with trained
PBP types. EA between the predicted PENMIC andmicrodilution
MIC was calculated for each year tested (Fig. 5). The year-specific
EA ranged from 91.4% to 100% with a median of 98.9% (Fig. 5).
We found no significant association between separation time and
year-specific percentage EA [Fig. 5, linear regression, t(13) 
1.59 and P 0.14].
DISCUSSION
In this study, we proposed a PBP typing system that links amino
acid sequence variation in the TPDs of PBP1a, PBP2b, and PBP2x
to -lactam MIC levels among invasive pneumococcal isolates.
FIG 3 Agreement between the predictedMIC and the microdilutionMIC among isolates of trained PBP types. The modeMIC (MM)model assigned the most
frequently seen MIC of a trained PBP type to a test isolate of the same PBP type. The random forest (RF) and elastic net (EN) models were designed to quantify
the contribution of each individual TPD position from the training data set and combine these contributions to make a prediction. See Materials and Methods
for detailed model description. The percent essential agreement (A), category agreement (B), major discrepancy (C), and very major discrepancy (D) were
calculated for six antibiotics. Error bars are 95% CIs.
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We found that PBP types containing divergent TPD variants—
those exhibiting more than 10% amino acid sequence difference
from the typical susceptible PBP type 2-0-2—were associatedwith
increased -lactamMICs. Isolates with high-level PEN resistance
commonly harbored a divergent TPD within all three PBPs. One
possible reason is that epistasis between pbp loci is essential for
these strains to maintain both high-level -lactam resistance and
fitness. The TPD positions in which amino acids frequently dif-
fered between susceptible and resistant isolates appeared to be
distributed nonrandomly. This may reflect structural constraints
dictating that only changes in specific TPD positions would allow
a viable, resistant TPD variant. Alternatively, this could indicate
that the observed resistant TPD sequences have not yet diverged
sufficiently from recent founder sequences. Additional studies are
needed to understand the relative contributions of these mecha-
nisms.
In genomically tracking -lactam resistance, a typing system
that correlates with the phenotype closely and robustly is desir-
able. Since sequence variations both within and outside the PBPs
have been reported to influence -lactam MICs (19, 20, 27), we
examined how much the phenotype could vary among isolates of
the same PBP type but of diverse genomic backgrounds as defined
byMLST. TheMICs within susceptible PBP types were very stable
regardless of genomic background. The results were consistent
with the notion that sequence variations outside the three TPDs
may alter the level of resistance in isolates carrying resistant PBPs,
but these variations rarely confer resistance themselves (28).
While the resistant PBP types tended to show larger MIC varia-
tions, there was no evidence that theMIC differed significantly by
MLST within the same PBP type. Several different factors could
explain the lack of association between MLST and MIC within a
PBP type. One possibility is that MLST failed to represent the
non-TPD variations actuallymodulatingMICs. Another possibil-
ity is that non-TPD variations influence MIC only minimally so
that there was not enough power to detect such effects. Nonethe-
less, analysis of variance showed that the PBP type, when incorpo-
rated into a model for random effect, explained the vast majority
of variation in -lactam MICs both before and after accounting
for MLST, suggesting that the PBP type was a dominant and ro-
bust determinant of -lactam MIC at the population level.
One practical application of our proposed PBP typing system is
to predict the -lactam resistance level based on sequence infor-
mation. This application could be important in developing sus-
ceptibility testing for clinical specimens from which an isolate
cannot be recovered. It may also facilitate estimating the preva-
lence and spread of -lactam resistance in the current era when
bacterial whole-genome sequencing data rapidly accumulate, yet
accompanying MIC information is not always available or reli-
able. Here we developed three basic models to predict -lactam
MICs based on PBP type. The simplest MM model just assigned
themost frequently seenMIC of a trained PBP type to a test isolate
of the same PBP type and approximated any nontrained PBP type
by the most closely related trained PBP type. The more-complex
RF and EN models were designed to quantify the contribution of
each individual TPD position from the training data set and com-
bine these contributions to make a prediction. PredictedMICs by
FIG 4 Agreement between the predictedMIC and themicrodilutionMIC among isolates of nontrained PBP types. ThemodeMIC (MM)model approximated
a nontrained PBP type by the most closely related trained PBP type and assigned the most frequently seenMIC of the trained PBP type to the test isolate. For the
random forest (RF) and elastic net (EN)models, any amino acid not seen in the training data set was approximated by a corresponding training amino acid with
the least BLOSUM62 distance. See Materials adMethods for detailed model description. (A and B) The rates of essential agreement (A) and category agreement
(B) were calculated for the six antibiotics. Error bars are 95% CIs. (C) Relationship between the number of amino acid (AA) differences and outcome of EA for
PEN MIC (in micrograms per milliliter) predicted by the MMmethod.
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MM and RF models showed essentially equivalence with the mi-
crodilutionMIC for trained PBP types but not for the nontrained
ones. The results supported the use of these predicted MICs as
valid susceptibility testing results for isolates of trained PBP types.
It is also important to obtain microdilution MICs for all newly
found PBP types, thus expanding the number of trained PBP
types. Better modeling design and more training data could help
identify conserved amino acid sites that are predictive of MICs in
other data sets. Characterizing the specific contributions of sub-
stitutions at these conserved, predictive sites is important because
the pneumococcal genome is highly plastic, precluding the docu-
mentation of all possible PBP types. Further, models that quantify
the contributions of individual TPD positions and/or their inter-
actions to -lactam MICs may provide insights into resistance
mechanisms and should be a priority of future investigation.
MATERIALS AND METHODS
Isolates and characterization. The study sample was 2,528 broadly rep-
resentative pneumococcal isolates selected from the Active Bacterial Core
surveillance (ABCs) over the years 1998 to 2015. ABCs is an active,
population-based and laboratory-based surveillance system that is part of
the Centers for Disease Control and Prevention’s (CDC) Emerging Infec-
tions Program. Cases of invasive pneumococcal diseases (IPD) were de-
fined by the isolation of pneumococci from a normally sterile site in res-
idents of the surveillance areas in 10 different states (29–31) (see ABCs
surveillance reports for population sizes, IPD incidence, antimicrobial
susceptibility data, and other information at http://www.cdc.gov/abcs/
reports-findings/surv-reports.html).
Isolates were characterized by a combination of conventional testing
and short-read whole-genome sequence (WGS) analysis. MICs for six
-lactam antibiotics, penicillin (PEN), amoxicillin (AMO), meropenem
(MER), cefotaxime (TAX), ceftriaxone (CFT), and cefuroxime (CFX),
were determined by the broth microdilution method as previously de-
scribed (32). MIC interpretive standards are shown in Table S3 in the
supplemental material and are consistent with CLSI document M100-23
(33). Unless otherwise specified, PEN susceptibility and resistance refer to
PEN MIC of0.06 and0.12 g/ml, respectively. When MIC was ana-
lyzed as a numeric variable, an MIC of “ X” was treated as value X; an
MIC of “X” was approximated as value X; and an MIC of “X” was
approximated as value 2X.
Multilocus sequence types (MLSTs) and the TPD amino acid se-
quences of PBP1a, PBP2b, and PBP2x were extracted using a validated
pneumococcal typing pipeline as described previously (34). Databases of
68, 78, and 118 unique TPD amino acid sequences were compiled for
PBP1a, PBP2b, and PBP2x, respectively (see Table S4 in the supplemental
material). Each unique TPD amino acid sequence was assigned an iden-
tifier, and the three-number combination from each isolate was assigned
as its “PBP type.” For example, PBP type 2-0-2 describes an isolate con-
taining a composite TPD amino acid sequence pattern of PBP1a-2,
PBP2b-0, and PBP2x-2. All isolates through 2013 were serotyped with
latex agglutination and the quellung reaction employing CDC antisera.
Serotypes of isolates recovered after 2013 were determined by WGS and
the typing pipeline (34).
PBP active site motifs (amino acid sequences) were defined as the
following according to Hakenbeck et al. (20): S370TMK, S466SN, and
K557TG in PBP1a, S386TMK, S443SN, and K614TG in PBP2b, and
S337TMK, S395SN, and K547SG in PBP2x. The position of a motif’s first
residue was used in calculating distance from an active site.
Analysis of variance for -lactam MIC. Mixed-effect models incor-
porating randomeffects for PBP type andMLSTwere used for the analysis
of variance. We chose mixed-effect models because the observed PBP
types andMLSTs represented a sample (subset) of all possible types in the
pneumococcal population. Additionally,mixed-effectmodels could facil-
itate the analysis of data that were unbalanced and contained cells of 0
count in a contingency table, which was the case for our study sample.
For each -lactam, four models were constructed with the log2-
transformed MIC as the dependent variable and using another or other
factors or variables as the covariate(s). Inmodel 1, onlyMLSTwas used as
a covariate. Inmodel 2, only PBP type was used as a covariate. Inmodel 3,
both PBP type and MLST were used as covariates. In model 4, PBP type,
MLST, and their interaction term were used as covariates. These models
FIG 5 Regression line showing the effect of time between the training and testing data sets on percent essential agreement (EA). Isolates in one of the surveillance
years 1998, 1999, 2009, 2012, and 2013 were used as the training data set for theMMmodel to predict PENMIC for isolates in subsequent years with trained PBP
types. The inset table shows percent EA (number of isolates used to calculate EA) in the indicated testing data set. Based on data in the table, the year-specific
percent EA was plotted against separation time between the training and testing data sets (open circles). A fitted linear regression line is shown (solid line).
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incorporated random effect(s) for all covariate(s). The only fixed-effect
term was the intercept. Nested models were compared by a likelihood
ratio test; a P value of 0.05 was considered evidence of significantly
better fit for themore-complexmodel. TheRpackage “lme4”was used for
model fitting and comparison. Model 4 showed no significant increase in
goodness of fit compared to model 3 for any -lactams and therefore was
excluded from further analysis.
Predictive models of -lactam MIC. The study sample (2,528 pneu-
mococcal isolates) was divided into a training data set and a test data set.
MICs in the test data set were predicted using models parameterized by
the training data set. We denoted a PBP type as “trained” if it was present
in the training data set with MIC data; otherwise, the PBP type was de-
noted as “nontrained.” In the “leave-one-out” cross-validation, which
represents a special case of dividing the study sample into training and test
data sets, each isolatewas used in turn as the testing data set, while all other
isolates were used as the training data set.
Three predictive models were evaluated: (i) mode MIC (MM) model,
(ii) random forest (RF) model, and (iii) elastic net (EN) model.
(i) MM model. In the mode MIC model, the highest MIC among the
most frequently observed MIC(s) for a PBP type in the training data set
was assigned as the predictedMICof the samePBP type in the test data set.
Any PBP type not seen in the training data set was approximated by a
training PBP type that showed the highest amino acid identity.
(ii) RF model. In the random forest model, we used the amino acid at
each position of the three TPDs as predictors to train an RFmodel for the
continuous outcome log2 (MIC). The trained model then predicted the
MIC of a test isolate based on its TPD amino acid sequence. For a given
position in the TPDs, any amino acid not seen in the training data set was
approximated by the training amino acid with the least BLOSUM62 dis-
tance. TheR package “randomForest” was used for RFmodel training and
prediction.
(iii) EN model. Similar to the RF model, the amino acid at each posi-
tion of the three TPDs was used as predictors to train an elastic net model
for the continuous outcome log2 (MIC). The R package “glmnet” was
used for EN model training and prediction.
To evaluate prediction performance, we calculated the essential agree-
ment (EA), category agreement (CA), very major discrepancy (vmj), and
major discrepancy (maj) between the predicted MIC (new method) and
brothmicrodilutionMIC (referencemethod) according to the FDA guid-
ance document for antimicrobial susceptibility test systems (35). Briefly,
the FDA guidance document’s definitions follow: CA, agreement of inter-
pretive results (susceptible [S], intermediate [I], or resistant [R]); EA,
agreement within (plus or minus) one twofold dilution of the reference
MIC; maj, the reference category result is S and the new method result
is R; vmj, the reference category result is R and the new method result
is S. Criteria for acceptable performance in the FDA guidance docu-
ment include (i) essential and category agreement of 89.9%; (ii) a
maj rate of 3%; and (iii) an upper 95% confidence limit for the true
vmj rate of7.5% and the lower 95% confidence limit for the true vmj
rate of 1.5%.
Statistics. Correlation between two numerical variables was quanti-
fied by Spearman’s rank correlation coefficient (). Association between
two categorical variables was evaluated by Fisher’s exact test. Equal me-
dian between two groups was examined by Mann-Whitney U test. Con-
fidence interval for proportion was constructed using the exact binomial
method. All statistical analyses were performed in R version 3.2.2 (36);
graphics were also created in R version 3.2.2.
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